References
[1] Lynch, H.T., Casey, M.J., Snyder, C.L., et al. (2009) Hereditary Ovarian Carcinoma: Heterogeneity, Molecular Genetics, Pathology, and Management. Molecular Oncology, 3, 97-137.
http://dx.doi.org/10.1016/j.molonc.2009.02.004
[2] Narod, S.A. (2011) Genetic Variants Associated with Breast-Cancer Risk. The Lancet Oncology, 12, 415-416.
http://dx.doi.org/10.1016/S1470-2045(11)70084-5
[3] Lord, C.J. and Ashworth, A. (2013) Mechanisms of Resistance to Therapies Targeting BRCA-Mutant Cancers. Nature Medicine, 19, 1381-1388.
http://dx.doi.org/10.1038/nm.3369
[4] Lee, J.M., Ledermann, J.A. and Kohn, E.C. (2014) PARP Inhibitors for BRCA1/2 Mutation-Associated and BRCA-Like Malignancies. Annals of Oncology, 25, 32-40.
http://dx.doi.org/10.1093/annonc/mdt384
[5] Karginova, O., Siegel, M.B., Van Swearingen, A.E., et al. (2015) Efficacy of Carboplatin Alone and in Combination with ABT888 in Intracranial Murine Models of BRCA-Mutated and BRCA-Wild-Type Triple-Negative Breast Cancer. Molecular Cancer Therapeutics, 14, 920-930.
http://dx.doi.org/10.1158/1535-7163.MCT-14-0474
[6] Rouleau, M., Patel, A., Hendzel, M.J., Kaufmann, S.H. and Poirier, G.G. (2010) PARP Inhibition: PARP1 and Beyond. Nature Reviews Cancer, 10, 293-301.
http://dx.doi.org/10.1038/nrc2812
[7] Shaw, H.M. and Hall, M. (2013) Emerging Treatment Options for Recurrent Ovarian Cancer: The Potential Role of Olaparib. OncoTargets and Therapy, 6, 1197-1206.
[8] Yamamoto, N., Nokihara, H., Yamada, Y., et al. (2012) A Phase I, Dose-Finding and Pharmacokinetic Study of Olaparib (AZD2281) in Japanese Patients with Advanced Solid Tumors. Cancer Science, 103, 504-509.
http://dx.doi.org/10.1111/j.1349-7006.2011.02179.x
[9] Fong, P.C., Yap, T.A., Boss, D.S., et al. (2010) Poly(ADP)-Ribose Polymerase Inhibition: Frequent Durable Responses in BRCA Carrier Ovarian Cancer Correlating with Platinum-Free Interval. Journal of Clinical Oncology, 28, 2512-2519.
http://dx.doi.org/10.1200/JCO.2009.26.9589
[10] Fong, P.C., Boss, D.S., Yap, T.A., et al. (2009) Inhibition of Poly(ADP-Ribose) Polymerase in Tumors from BRCA Mutation Carriers. The New England Journal of Medicine, 361, 123-134.
http://dx.doi.org/10.1056/NEJMoa0900212
[11] Marchetti, C., Imperiale, L., Gasparri, M.L., Palaia, I., Pignata, S., Boni, T., et al. (2012) Olaparib, PARP1 Inhibitor in Ovarian Cancer. Expert Opinion on Investigational Drugs, 21, 1575-1584.
http://dx.doi.org/10.1517/13543784.2012.707189
[12] Ledermann, J., Harter, P., Gourley, C., Friedlander, M., Vergote, I., Rustin, G., et al. (2012) Olaparib Maintenance Therapy in Platinum-Sensitive Relapsed Ovarian Cancer. New England Journal of Medicine, 366, 1382-1392.
http://dx.doi.org/10.1056/NEJMoa1105535
[13] Audeh, M.W., Carmichael, J., Penson, R.T., Friedlander, M., Powell, B., Bell-McGuinn, K.M., et al. (2010) Oral Poly(ADP-ribose) Polymerase Inhibitor Olaparib in Patients with BRCA1 or BRCA2 Mutations and Recurrent Ovarian Cancer: A Proof-of-Concept Trial. The Lancet, 376, 245-251.
http://dx.doi.org/10.1016/S0140-6736(10)60893-8
[14] Tutt, A., Robson, M., Garber, J.E., Domchek, S.M., Audeh, M.W., Weitzel, J.N., et al. (2010) Oral Poly(ADP-ribose) Polymerase Inhibitor Olaparib in Patients with BRCA1 or BRCA2 Mutations and Advanced Breast Cancer: A Proof-of-Concept Trial. The Lancet, 376, 235-244.
http://dx.doi.org/10.1016/S0140-6736(10)60892-6
[15] Mahaney, B.L., Meek, K. and Lees-Miller, S.P. (2009) Repair of Ionizing Radiation-Induced DNA Double-Strand Breaks by Non-Homologous End-Joining. Biochemical Journal, 417, 639-650.
http://dx.doi.org/10.1042/BJ20080413
[16] Jadad, A.R., Moore, R.A., Carroll, D., Jenkinson, C., Reynolds, D.J.M., Gavaghan, D.J. and McQuay, H.J. (1996) Assessing the Quality of Reports of Randomized Clinical Trials: Is Blinding Necessary? Controlled Clinical Trials, 17, 1-12.
http://dx.doi.org/10.1016/0197-2456(95)00134-4
[17] Phillips, B., Ball, C., Sackett, D., Badenoch, D., Straus, S., Haynes, B. and Dawes, M. (2009) Oxford Centre for Evidence-Based Medicine—Levels of Evidence (March 2009).
http://www.cebm.net
[18] Gelmon, K.A., Tischkowitz, M., Mackay, H., Swenerton, K., Robidoux, A., Tonkin, K., et al. (2011) Olaparib in Patients with Recurrent High-Grade Serous or Poorly Differentiated Ovarian Carcinoma or Triple-Negative Breast Cancer: A Phase 2, Multicentre, Open-Label, Non-Randomised Study. The Lancet Oncology, 12, 852-861.
http://dx.doi.org/10.1016/S1470-2045(11)70214-5
[19] Kaye, S.B., Lubinski, J., Matulonis, U., Ang, J.E., Gourley, C., Karlan, B.Y., et al. (2012) Phase II, Open-Label, Randomized, Multicenter Study Comparing the Efficacy and Safety of Olaparib, a Poly(ADP-ribose) Polymerase Inhibitor, and Pegylated Liposomal Doxorubicin in Patients with BRCA1 or BRCA2 Mutations and Recurrent Ovarian Cancer. Journal of Clinical Oncology, 30, 372-379.
http://dx.doi.org/10.1200/JCO.2011.36.9215
[20] Kaufman, B., Shapira-Frommer, R., Schmutzler, R.K., Audeh, M.W., Friedlander, M., Balmaña, J., et al. (2015) Olaparib Monotherapy in Patients with Advanced Cancer and a Germline BRCA1/2 Mutation. Journal of Clinical Oncology, 33, 244-250.
http://dx.doi.org/10.1200/JCO.2014.56.2728
[21] Hall, M. and Rustin, G. (2011) Recurrent Ovarian Cancer: When and How to Treat. Current Oncology Reports, 13, 459-471.
http://dx.doi.org/10.1007/s11912-011-0199-3
[22] Liu, J.F., Barry, W.T., Birrer, M., Lee, J.-M., Buckanovich, R.J., Fleming, G.F., et al. (2014) Combination Cediranib and Olaparib versus Olaparib Alone for Women with Recurrent Platinum-Sensitive Ovarian Cancer: A Randomised Phase 2 Study. The Lancet Oncology, 15, 1207-1214.
http://dx.doi.org/10.1016/S1470-2045(14)70391-2
[23] Ledermann, J., Harter, P., Gourley, C., Friedlander, M., Vergote, I., Rustin, G., et al. (2014) Olaparib Maintenance Therapy in Patients with Platinum-Sensitive Relapsed Serous Ovarian Cancer: A Preplanned Retrospective Analysis of Outcomes by BRCA Status in a Randomised Phase 2 Trial. The Lancet Oncology, 15, 852-861.
http://dx.doi.org/10.1016/S1470-2045(14)70228-1
[24] Ledermann, J.A. and Raja, F.A. (2011) Clinical Trials and Decision-Making Strategies for Optimal Treatment of Relapsed Ovarian Cancer. European Journal of Cancer, 47, S104-S115.
http://dx.doi.org/10.1016/s0959-8049(11)70154-x
[25] Raja, F.A., Counsell, N., Colombo, N., Pfisterer, J., du Bois, A., Parmar, M.K., et al. (2013) Platinum versus Platinum-Combination Chemotherapy in Platinum-Sensitive Recurrent Ovarian Cancer: A Meta-Analysis Using Individual Patient Data. Annals of Oncology, 24, 3028-3034.
http://dx.doi.org/10.1093/annonc/mdt406
[26] Monk, B.J., Herzog, T.J., Kaye, S.B., Krasner, C.N., Vermorken, J.B., Muggia, F.M., et al. (2010) Trabectedin plus Pegylated Liposomal Doxorubicin in Recurrent Ovarian Cancer. Journal of Clinical Oncology, 28, 3107-3114.
http://dx.doi.org/10.1200/JCO.2009.25.4037
[27] Bayraktar, S. and Gluck, S. (2012) Systemic Therapy Options in BRCA Mutation-Associated Breast Cancer. Breast Cancer Research and Treatment, 135, 355-366.
http://dx.doi.org/10.1007/s10549-012-2158-6
[28] Sandhu, S.K., Schelman, W.R., Wilding, G., Moreno, V., Baird, R.D., Miranda, S., et al. (2013) The Poly(ADP-ribose) Polymerase Inhibitor Niraparib (MK4827) in BRCA Mutation Carriers and Patients with Sporadic Cancer: A Phase 1 Dose-Escalation Trial. The Lancet Oncology, 14, 882-892.
http://dx.doi.org/10.1016/S1470-2045(13)70240-7
[29] O’Shaughnessy, J., Schwartzberg, L., Danso, M.A., Miller, K.D., Rugo, H.S., Neubauer, M., et al. (2014) Phase III Study of Iniparib plus Gemcitabine and Carboplatin versus Gemcitabine and Carboplatin in Patients with Metastatic Triple-Negative Breast Cancer. Journal of Clinical Oncology, 32, 3840-3847.
http://dx.doi.org/10.1200/JCO.2014.55.2984
[30] Moore, K.N., DiSilvestro, P. and Lowe, E.S. (2014) SOLO1 and SOLO2 Randomized Phase III Trials of Olaparib in Patients (pts) with Ovarian Cancer and a BRCA12 Mutation (BRCAm). ASCO Annual Meeting 2014, Chicago, 30 May-3 June 2014, TPS5616 [Abstract].